SEC Form SC 13G filed by Zenas BioPharma Inc.

11/12/24 10:40:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZBIO alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ZENAS BIOPHARMA INC COMMON STOCK Cusip #98937L105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98937L105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,000,000 Item 6: 0 Item 7: 2,000,000 Item 8: 0 Item 9: 2,000,000 Item 11: 5.026% Item 12: HC Cusip #98937L105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,000,000 Item 8: 0 Item 9: 2,000,000 Item 11: 5.026% Item 12: IN Item 1(a). Name of Issuer: ZENAS BIOPHARMA INC Item 1(b). Address of Issuer's Principal Executive Offices: 1000 WINTER ST, SUITE 1200 WALTHAM, MA 02451 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 98937L105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,000,000 (b) Percent of Class: 5.026% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,000,000 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ZENAS BIOPHARMA INC. No one other person's interest in the COMMON STOCK of ZENAS BIOPHARMA INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ZENAS BIOPHARMA INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ZBIO alert in real time by email

Recent Analyst Ratings for

$ZBIO

Date	Price Target	Rating	Analyst
3/20/2025	$35.00	Outperform	Wedbush
2/4/2025	$19.00	Outperform	Wolfe Research
12/16/2024	$30.00	Buy	H.C. Wainwright
11/5/2024	$34.00	Buy	Rodman & Renshaw
10/8/2024	$45.00	Buy	Guggenheim
10/8/2024	$40.00	Overweight	Morgan Stanley
10/8/2024	$35.00	Buy	Jefferies
10/8/2024	$27.00	Buy	Citigroup

More analyst ratings

SEC Form SC 13G filed by Zenas BioPharma Inc.

11/12/24 10:40:28 AM ET

$ZBIO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZBIO alert in real time by email

Recent Analyst Ratings for

$ZBIO

Date	Price Target	Rating	Analyst
3/20/2025	$35.00	Outperform	Wedbush
2/4/2025	$19.00	Outperform	Wolfe Research
12/16/2024	$30.00	Buy	H.C. Wainwright
11/5/2024	$34.00	Buy	Rodman & Renshaw
10/8/2024	$45.00	Buy	Guggenheim
10/8/2024	$40.00	Overweight	Morgan Stanley
10/8/2024	$35.00	Buy	Jefferies
10/8/2024	$27.00	Buy	Citigroup

More analyst ratings

SEC Form SC 13G filed by Zenas BioPharma Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ZBIO

SEC Form SC 13G filed by Zenas BioPharma Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ZBIO

$ZBIO
Analyst Ratings

Wedbush initiated coverage on Zenas Biopharma with a new price target

Wolfe Research initiated coverage on Zenas Biopharma with a new price target

H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

$ZBIO
Insider Purchases

Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

$ZBIO
Press Releases

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

$ZBIO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

Zenas BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Zenas BioPharma Inc.

$ZBIO
Insider Trading

SEC Form 4 filed by Director Nunn Jason Raleigh

SEC Form 4 filed by Officer Fox Jennifer A.

SEC Form 4 filed by Officer Oliveira Orlando

$ZBIO
Leadership Updates

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

$ZBIO
Financials

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

$ZBIO
Large Ownership Changes